Search This Blog

Wednesday, November 4, 2020

Health Insurance Stocks Soar As Sector Avoids Worst-Case Election Scenario

Votes are still being counted in the U.S. presidential election, but health care facility and managed care stocks appear to have avoided a worst-case scenario. 

No Blue Wave: On Wednesday, BofA Securities analyst Kevin Fischbeck said the fact that Democrats appear unlikely to have secured a Senate majority makes the possibility of significant health care reform unlikely.

 

“We see a split Congress/slim majority as a positive scenario for Managed Care and Healthcare facilities as broad, sweeping changes like implementing a public option, raising taxes or lowering the Medicare age are likely off the table, increasing visibility for at least another two years,” the analyst said in a note. 

Stocks On The Move: As a result, Fischbeck said health care facility and managed care stocks likely have near-term upside, led by Humana Inc HUM 6.27% and UnitedHealth Group Inc UNH 11.62%

Humana shares were up 6.3% at last check Wednesday and UnitedHealth shares were up 10.87%. 

When it comes to the presidential race — which could be headed for recounts and/or court challenges — Fischbeck said a Donald Trump victory would represent the status quo in the health care sector and would be a positive for investors.

Yet a Joe Biden victory and a split Congress would also be bullish, the analyst said.

While Biden would likely be able to do things to shore up and fund the Affordable Care Act, he will likely not be able to make any sweeping reforms without support from the Senate, according to BofA. 

In addition to the big moves in Humana and UnitedHeath, shares of Anthem Inc ANTM 12.37% were up 9.3% and shares of Cigna Corp CI 13.89% were up 12.55% Wednesday. 

Benzinga’s Take: It appears health care facility and managed care stocks were pricing in a high likelihood of a blue wave victory for Democrats, an outcome that appears unlikely at this point.

Gridlock in Washington limits the possibility of disruptive health care reforms that could potentially eat into earnings and limit long-term visibility.

https://www.benzinga.com/analyst-ratings/analyst-color/20/11/18209005/health-insurance-stocks-soar-as-sector-avoids-worst-case-election-scenario

AstraZeneca missed COVID-19 vaccine delivery target in U.K.

The Financial Times reports that AstraZeneca (AZN +6.7%) missed its target of delivering 30M doses of its COVID-19 vaccine, currently dubbed AZD1222, to the U.K. by the end of September.

AstraZeneca Q3 2020 Earnings Preview

EU drug watchdog won't set minimum efficacy levels for potential COVID-19 vaccines

Europe's drug regulator will not set a minimum level of efficacy for potential COVID-19 vaccines when considering them for approval, it said on Wednesday, taking a different approach to that of its U.S. counterpart.

Human studies need to demonstrate a convincing level of efficacy, but whether a shot would be considered acceptable for approval will be assessed case by case based on all available data on its safety and efficacy, the European Medicines Agency (EMA) said in an email.

"Therefore it is not possible to specifically quantify in advance the minimum level of efficacy for a vaccine to be considered acceptable for approval," it said.

The U.S. Food and Drug Administration has said vaccines must demonstrate at least 50% efficacy - meaning at least twice as many infections among volunteers who got a placebo as among those in the vaccine group.

The EMA is reviewing candidate vaccines by drug makers Pfizer, AstraZeneca and Moderna under a real-time release process, in an effort to speed up the approval if trials of any of those vaccines are successful. They are undergoing late-stage trials.

The EMA said on Wednesday its human medicines committee (CHMP) is drawing up guidance on its requirements for COVID-19 vaccine approval and will publish the information as soon as it is ready.

https://www.marketscreener.com/quote/stock/ASTRAZENECA-PLC-4000930/news/AstraZeneca-EU-drug-watchdog-won-t-set-minimum-efficacy-levels-for-potential-COVID-19-vaccines-31689346/

Rocket Pharma Reports 3Q, Highlights Recent Progress

—Positive Phase 1 Study Results of RP-L201 for the Treatment of LAD-I Demonstrate Ongoing Efficacy, Durability and Validation of Rocket’s "Process B" Lentiviral Platform—

—Data Readouts in PKD, FA "Process B" and Danon Disease on Track for December—

—First Patient Treated in Higher Dose Cohort of Phase 1 Study of RP-A501 for the Treatment of Danon Disease—

—Strong Balance Sheet with $229 Million in Cash; Capitalized into 2Q 2022—

https://finance.yahoo.com/news/rocket-pharmaceuticals-reports-third-quarter-120000255.html

Cassava Sciences Has More Data from Phase 2b Study of Sumifilam in Alzheimer’s

Alzheimer’s Patients Treated with Sumifilam Showed a Statistically Significant (p<0.001) Treatment Benefit on HMGB1,
a Protein that Triggers Neuroinflammation and Loss of Neurons

Alzheimer’s Patients Treated with Sumifilam Also Showed
a Treatment Benefit (p<0.05) on Blood-brain Barrier Integrity

Clinical Dataset to be Presented November 7th at CTAD 2020 Conference

https://finance.yahoo.com/news/cassava-sciences-announces-additional-clinical-131500100.html

Biogen Alzheimer's drug gets FDA staff's backing ahead approval meet

Biogen Inc's experimental Alzheimer's disease drug was found effective enough in a large trial to support approval, U.S. Food and Drug Administration staff said on Wednesday, potentially making it the first drug to be approved in decades to slow down the progress of the memory robbing disease.

The FDA staff's comments that come ahead of a meeting of a panel of independent advisers to the health regulator on Friday sent shares of the company soaring 30%.

Cambridge, Massachusetts-based Biogen in October last year revived its plans to seek approval for the drug, months after it had said that a "futility analysis" from two studies of the drug showed it was unlikely to pass the trials.

Biogen said it changed plans after a new analysis of the two studies showed a high dose of the drug could slow the disease's progression.

Some Wall Street analysts remain skeptical of the drug, as one of those two studies failed its main goal.

The FDA staff said one of the two studies "provides the primary evidence of effectiveness as a robust and exceptionally persuasive study demonstrating a treatment effect on a clinically meaningful endpoint."

A final decision on the drug, jointly developed with Japan's Eisai Co Ltd, is due by March 2021.

https://finance.yahoo.com/news/biogen-alzheimers-drug-gets-u-154154615.html